TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

About this update from Tg Therapeutics, Inc.

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy therapy NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis (RMS). The article, titled “Disease outcomes with ublituximab in treatment-naïve participants: Subpopulation analyses of the Phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis,” authored by Derrick Robertson, MD, of the University of South Florida, Tampa, FL and colleagues, was published in Frontiers in Immunology. These post-hoc analyses demonstrate that BRIUMVI provided significant and consistent improvements across multiple clinical and MRI endpoints compared to teriflunomide in patients who had not received a prior disease-modifying therapy, including those treated early in their disease course. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “Publication of these treatment-naïve analyses further reinforces the compelling efficacy profile of BRIUMVI, particularly in patients early in their disease journey. These findings add to the growing body of evidence supporting the early use of high-efficacy therapies to help improve long-term outcomes for people living with relapsing multiple sclerosis.” The article can be accessed at the Frontiers in Immunology website or on our TG website at https://www.tgtherapeutics.com/publications/. OVERVIEW OF ARTICLEThese analyses evaluated pooled data from the Phase 3 ULTIMATE I and II trials in patients who had not received prior disease-modifying therapy, including a subset of people treated within three years of symptom onset. Outcomes were assessed over 96 weeks of treatment. Key Efficacy Results ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patient...

View stock analysis, news, and events for Tg Therapeutics, Inc.